Key Takeaways:
- Biogen Inc. (BIIB, Financial) posts strong quarterly results with non-GAAP EPS of $3.02.
- Analyst consensus targets an average price increase of nearly 49% for BIIB.
- GuruFocus projects a potential 75% upside based on GF Value estimates.
Biogen Inc. (BIIB) reported robust financial performance for the last quarter, which included non-GAAP earnings per share of $3.02 and a revenue total of $2.43 billion. As the company prepares for its upcoming earnings preview for Q1 2025 and its participation in the Stifel 2025 Virtual CNS Forum Conference, it's drawing significant attention from investors and analysts alike.
Wall Street Analysts Forecast
The financial community is optimistic about Biogen, as evidenced by the one-year price targets set by 29 analysts. The average target price is pegged at $180.15, with projections ranging from a high of $300.00 to a low of $115.00. This implies a promising upside potential of 48.79% from the current stock price of $121.08. For a deeper dive into these estimates, visit the Biogen Inc (BIIB, Financial) Forecast page.
Brokerage firms seem to share this positive sentiment, with 37 firms giving Biogen Inc. an average recommendation of 2.5, which translates to an "Outperform" rating. This recommendation uses a scale from 1 to 5, where 1 is a Strong Buy and 5 is a Sell.
Additionally, GuruFocus estimates a GF Value for Biogen Inc. at $211.92 within the next year. This suggests an impressive potential upside of 75.02% from the present stock price of $121.08. The GF Value is calculated based on historical trading multiples, past growth trends, and future business performance projections. For more comprehensive insights, check the Biogen Inc (BIIB, Financial) Summary page.
